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Site-specific incorporation of unnatural amino acids (UAAs) into
proteins is a valuable tool for studying structure–function rela-
tionships, incorporating biophysical probes, and elucidating pro-
tein–protein interactions. In higher eukaryotic cells, the method-
ology is currently limited to incorporation of a single UAA in
response to a stop codon, which is known as nonsense suppres-
sion. Frameshift suppression is a unique methodology for incor-
porating UAAs in response to quadruplet codons, but currently, it
is mostly limited to in vitro protein translation systems. Here, we
evaluate the viability of frameshift suppression in Xenopus oo-
cytes. We demonstrate UAA incorporation by using yeast phenyl-
alanine frameshift suppressor (YFFS) tRNAs that recognize two
different quadruplet codons (CGGG and GGGU) in vivo. Suppres-
sion efficiency of the YFFS tRNAs increases nonlinearly with the
amount of injected tRNA, suggesting a significant competition
with endogenous, triplet-recognizing tRNA. Both frameshift sup-
pressor tRNAs are less efficient than the amber suppressor tRNA
THG73 (Tetrahymena thermophila G73), which has been used
extensively for UAA incorporation in Xenopus oocytes. However,
the two YFFS tRNAs are more ‘‘orthogonal’’ to the Xenopus system
than THG73, and they offer a viable replacement when suppressing
at promiscuous sites. To illustrate the potential of combining
nonsense and frameshift suppression, we have site-specifically
incorporated two and three UAAs simultaneously into a neuro-
receptor expressed in vivo.
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The site-specific incorporation of unnatural amino acids (UAAs)into proteins biosynthetically is a powerful methodology that is
seeing increasing use. The primary approach has been stop codon
(nonsense) suppression using a specially designed tRNA with an
anticodon that recognizes the stop codon. A wide range of in vitro
translation systems has been used, along with expression in Esch-
erichia coli and, to a lesser extent, yeast. Nonsense suppression in
higher eukaryotes has, for the most part, been limited to the
Xenopus oocyte, where microinjection of the required mRNA and
aminoacyl tRNA is straightforward and electrophysiology provides
a sensitive probe of UAA incorporation (1, 2). Other experiments
in higher eukaryotes have relied on the evolution of a unique tRNA
and a complementary aminoacyl-tRNA synthetase (aaRS) to insert
a UAA in response to the UAG orUGA stop codon, but currently,
only 3-iodo-tyrosine (3), p-benzoyl-phenylalanine (4), and 5-
hydroxy-tryptophan (5) have been incorporated.
A remarkable variant of this approach is the use of quadruplet
codons, a process that is termed frameshift suppression and was
pioneered by Sisido and coworkers (6, 7). The success of this
approach opens up the possibility of developing multiple additional
codons, thus incorporating several different UAAs into a protein.
This multiple incorporation, in turn, would enable the use of
innovative biophysical approaches such as incorporating FRET
pairs, structural probes such as unique cross-linking approaches,
and more detailed structure–function studies.
To date, frameshift suppression in vivo has been performed only
in E. coli by using a unique tRNAaaRS pair, and homoglutamine
is the only UAA incorporated by this method. Frameshift suppres-
sion was used simultaneously with nonsense suppression to incor-
porate two UAAs in E. coli (8). It has yet to be established whether
frameshift suppression by chemically aminoacylated tRNA can be
effective in vivo in general and in eukaryotic cells such as the
Xenopus oocyte in particular. In fact, a previous attempt to perform
frameshift suppression in Xenopus oocytes showed very poor
suppression efficiency (9). Here, we show that with appropriately
designed frameshift suppressor (FS) tRNAs, frameshift suppres-
sion is a viable approach to UAA incorporation in eukaryotic cells.
Also, the efficiency of frameshift suppression can be substantially
improved by ‘‘masking’’ the mRNA of all in-frame quadruplet
sequences that match the frameshift suppression site. In particular,
we describe two tRNAs with four-base anticodons that can deliver
UAAs in response to the quadruplet codons CGGG and GGGU.
When directly compared with an amber suppressor (AS) tRNA
(THG73, Tetrahymena thermophilaG73) that has been used exten-
sively in Xenopus oocytes, the FS tRNAs are less efficient at
deliveringUAAs.However, both FS tRNAs aremore ‘‘orthogonal’’
than THG73, producing much less incorporation of undesired
natural amino acids at promiscuous sites. We also show that
suppression by FS tRNAs increases nonlinearly with the amount of
injected tRNA. To illustrate the potential of this methodology, we
have successfully incorporated two and three different UAAs
simultaneously into a neuroreceptor expressed in aXenopus oocyte.
Results
Testing Frameshift Suppression Viability in Vivo. To determine
whether frameshift suppression is viable in Xenopus oocytes, we
chose to use a tRNA that can be aminoacylated in vivo.We selected
the human serine AS (HSAS), because it is aminoacylated (with
serine) in eukaryotic cells and the seryl-tRNA synthetase does not
recognize the anticodon (10–12). The CUA anticodon of HSAS
was replaced with CCCG and ACCC to create the human serine
FSs (HSFSCCCG and HSFSACCC) (cloverleaf structures shown in
Fig. 1A), which recognize the quadruplet codons CGGG and
GGGU. Prior research showed that these four-base codons are
efficient in vitro (7). Injection of wild-type muscle nicotinic acetyl-
choline receptor (nAChR) mRNA and either HSFSCCCG or
HSFSACCC (2.5 or 10 ng per oocyte; no amino acid ligated to the
tRNA) into Xenopus oocytes resulted in no detectable channel
expression. The addition of the original AS HSAS with wild-type
nAChR mRNA did show channel expression with 2.5 ng of tRNA
per oocyte but not with 10 ng. These results suggested that the
HSFS tRNAs were causing1 frameshifts, resulting in undesirable
truncation of wild-type protein and thus a lack of detectable
current. Analysis of the four nAChR subunits revealed four CGGG
and one GGGU in-frame quadruplet codons, which were mutated
to degenerate codons (see Materials and Methods) to avoid sup-
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pression. We refer to the resulting mRNAs as the ‘‘masked’’
constructs. Other groups have similarly removed undesired in-
frame quadruplets (7, 9, 13). Injection of 2.5 ng per oocyte of either
unligated HSFS plus the masked nAChR mRNAs resulted in
functional channels with the same EC50 as channels expressed
without tRNA (data not shown). Unless otherwise noted, all
subsequent experiments used such masked constructs.
To test whether a naturally occurring amino acid (serine) could
be incorporated in response to a quadruplet codon, we probed a
highly conserved leucine of the nAChR M2 domain, a site desig-
nated Leu-9. This site is a promiscuous site in the nicotinic
receptor, and replacement of the native leucine with essentially any
natural amino acid produces a functional receptor, usually with a
quite noticeable shift in EC50. In particular, prior research showed
that a leucine-to-serine mutation in the -subunit (9) resulted in
an33-fold increased sensitivity to acetylcholine (ACh) (14). This
site was mutated to UAG, CGGG, or GGGU. When mutant
mRNA was injected into Xenopus oocytes along with 2.5 ng of
unligated HSAS or HSFS tRNA, which should be aminoacylated
with serine by the endogenous seryl-tRNA synthetase, significant
channel expression was seen. However, the EC50 values varied
depending on the incubation time (Table 1). This finding suggested
that natural amino acids other than serine were being placed at the
9 site with 2-day incubations, because the conventional mutant,
9Ser, shows no change in EC50 (Table 1). The variability in EC50
between 1- and 2-day incubations suggests that the tRNAs are being
modified to accept other amino acids. Modification of yeast phe-
nylalanine tRNA in Xenopus oocytes has been shown to increase
greatly from 1- to 2- day incubation times (15). Thus, we avoid this
complication by incubation for 1 day. Amber suppression is highly
efficient when the averagemaximal peak current (Imax) is measured
at 1.25 ng of tRNA per oocyte and decreases slightly when 2.5 ng
is added (Table 2). CGGG shows lower suppression than GGGU,
in agreement with previous in vitro studies (7, 16). CGGG suppres-
sion is highly nonlinear, with a 330% increase in current when twice
as much tRNA is injected (Table 2). GGGU, however, shows an
almost linear relationship, with an increase of 86% in response to
doubling (Table 2). These data suggest that HSFSACCC is a more
efficient tRNA at recognizing its cognate quadruplet codon andor
has less competition with endogenous triplet tRNA in Xenopus
oocytes than HSFSCCCG. These experiments establish that frame-
shift suppression is viable in Xenopus oocytes and that UAA
incorporation should be feasible when using the appropriate
FS tRNA.
UAA Incorporation by Frameshift Suppression. THG73 is an AS
tRNA (cloverleaf structure shown in Fig. 1A) (17) that is used
extensively for incorporating UAAs into various ion channels
expressed in Xenopus oocytes (2). Initially, a FS derived from
THG73 that recognizes the quadruplet codon CGGG
(THG73FSCCCG) was tested for UAA incorporation. Attempts to
suppress 9CGGG with THG73FSCCCG-L, where L was chemi-
cally aminoacylated onto the tRNA, showed no current in vivo. This
result is consistent with data fromVoss and coworkers (9), who saw
Fig. 1. tRNAs and UAAs. (A) The AS tRNAs are shown, with the CUA anticodon and the FS anticodons shown at the bottom. YFaFS tRNA acceptor stem mutations
are shown next to the YFFS tRNA body (italicized). (B) The three UAAs used in this study.
Table 1. HSAS and HSFS suppression experiments at the 9 site
9X tRNA, 2.5 ng EC50, 1 day* nH n EC50, 2 days* nH n
AGC (serine) none 1.5  0.04 1.7  0.07 5 1.5  0.2 1.9  0.3 3
UAG HSAS 1.7  0.06 1.7  0.09 6 0.70  0.008 1.9  0.07 14
CGGG HSFSCCCG 2.1  0.09 1.7  0.1 8 1.3  0.1 1.9  0.3 13
GGGU HSFSACCC 1.9  0.08 1.5  0.08 9 0.68  0.1 1.7  0.04 5
*Incubation time.








very little UAA incorporation with THG73FSACCC in Xenopus
oocytes.
We then chose to screen yeast phenylalanine FS (YFFS) tRNA,
which was used successfully by Sisido and colleagues (7, 16) in vitro.
We studied both YFFSCCCG and YFaFSACCC (yeast phenyalanine
containing acceptor stem mutations FS); Fig. 1A shows cloverleaf
structures. The latter contains acceptor stemmutations (denoted by
the ‘‘a’’) incorporated to reduce glycyl-tRNA synthetase recogni-
tion (7). We first evaluated a nonpromiscuous position of the
nAChR, 149W, an agonist-binding site tryptophan that makes a
cation- interaction with ACh (18). Wild-type recovery (i.e.,
suppressing the 149 quadruplet codons with YFFSCCCG-W or
YFaFSACCC-W) resulted in functional, wild-type channels (Table
3). TodemonstrateUAA incorporation,we relied onpreviouswork
using the AS THG73 that established that 5-fluoro-tryptophan
(WF1) (structure shown in Fig. 1B) incorporated at149 decreased
the cation- interaction and caused an 4-fold increase in EC50
(18). YFFSCCCG-WF1 suppression at 149CGGG resulted in a
comparable increase in EC50 (Table 3), establishing the successful
incorporation of the UAA WF1.
We next considered the previously mentioned Leu-9 residue.
Suppression at 9GGGU and 9GGGU with YFaFSACCC-Aba
(where Aba is -aminobutyric acid) and YFaFSACCC-Nval (where
Nval is norvaline) (UAA structures shown in Fig. 1B), respectively,
resulted in reductions in EC50 (Table 3) that were consistent with
previous studies that used the sameUAAs and theASTHG73 (14).
All frameshift suppression experiments had an Imax between 1.6
and4.4 A, which is more than adequate for UAA studies in vivo
and should allow for the incorporation of multiple UAAs. In all
cases, injection of full-length tRNA that had no amino acid attached
to the 3 end resulted in no detectable currents in response to added
ACh, directly showing a lack of aminoacylation by endogenous
Xenopus aaRSs.
Masking Effects on Frameshift Suppression. Experiments with HSFS
required the masking of the nAChR subunits to avoid protein
truncation caused by1 frameshifts. To demonstrate the effect on
UAA incorporation, suppression experiments were performed
with wild-type and masked constructs. The quadruplet codon
GGGU was chosen because there was only one in-frame quadru-
plet in the signaling sequence of the nAChR -subunit and none in
the -, -, or -subunits. Wild-type recovery was performed by
suppressing at 149GGGU with YFaFSACCC-W and adding either
wild-type or masked  mRNA to the injection mixture. Table 6,
which is published as supporting information on the PNASweb site,
shows the dramatic effect of masking one position on frameshift
suppression. With a 1:1:1:1 ratio of :::, the masked construct
gives a 2.7-fold increase in Imax relative to wild type. As the amount
of -subunit (which contains the suppression site) is increased, the
masking effect decreases to 1.5-fold and 1.2-fold with subunit ratios
of 5:1:1:1 and 10:1:1:1, respectively. Calculations that assume two
equally efficient quadruplet codons reproduce this trend (Table 6),
suggesting that the 149GGGU and the GGGU present in the
-subunit have similar suppression efficiencies.
Comparison of Frameshift and Nonsense Suppression Efficiencies. To
compare frameshift and nonsense suppression, the 149 and 9
sites were studied in more detail. Suppression of 149CGGG or
GGGU with 10 ng of YFFSCCCG-W or YFaFSACCC-W resulted in
38% and 48%, respectively, of the current from 10 ng of THG73-W
suppression at 149UAG (Table 4). Suppression of 9UAG with
2 ng of THG73-L resulted in the largest Imax (Table 4). Suppression
at 9CGGG or GGGU with 2 ng of YFFSCCCG-L or YFaF-
SACCC-L resulted in 14% and 36%, respectively, of the current from
THG73-L (Table 4). We conclude that amber suppression is more
efficient than frameshift suppression, in agreement with a trend
previously seen in a eukaryotic cell-free translation system (16). In
particular, the suppression efficiency observed here follows the
order: THG73  YFaFSACCC  YFFSCCCG.
Interestingly, the yield of receptors from frameshift suppression
at the 9 site was substantially improved by increasing the amount
of tRNA injected. Suppression with 6 ng of YFFSCCCG-L or
Table 2. HSAS and HSFS suppression experiments at the 9 site (1-day incubation)
9X tRNA Imax  SE,* 1.25† n Imax  SE,* 2.5† n % HSAS, 1.25† % HSAS, 2.5† % change‡
UAG HSAS 19  2 12 14  3 11 100 100 26
CGGG HSFSCCCG 1.3  0.3 10 5.6  1 12 6.8 40 330
GGGU HSFSACCC 8.6  3 10 16  3 12 45 110 86
*Average Imax (in A) recorded at 50 M ACh.
†Nanograms of tRNA.
‡Between 1.25 and 2.5 ng.
Table 3. Wild-type recovery and UAA incorporation by
frameshift suppression in vivo
mRNA tRNA EC50 (theoretical)* nH n
149CGGG YFFSCCCG-W† 56  2 (50)‡ 1.8  0.07 8
149GGGU YFaFSACCC-W† 53  2 (50)‡ 1.6  0.03 8
9GGGU YFaFSACCC-Aba 16  0.9 (16)‡ 1.3  0.08 7
9GGGU YFaFSACCC-Nval 31  2 (36)‡ 1.6  0.1 6
149CGGG YFFSCCCG-WF1 190  3 (200)§ 1.6  0.03 10
*EC50 values from THG73-UAA incorporation by nonsense suppression.
†Rescue of wild-type recovery by frameshift suppression.
‡Ref. 14.
§Ref. 18.
Table 4. Comparison of suppression efficiency, aminoacylation,
and read-through in vivo
mRNA tRNA
tRNA,
ng n Imax  SE*
% THG73
or % UAG
149UAG THG73-W 10 18 4.8  2 100†
149CGGG YFFSCCCG-W 10 20 1.8  0.3 38†
149GGGU YFaFSACCC-W 10 13 2.3  0.9 48†
9UAG THG73-L‡ 2 15 6.1  2 100†
9CGGG YFFSCCCG-L‡ 2 12 0.84  0.2 14†
9GGGU YFaFSACCC-L‡ 2 9 2.2  0.5 36†
9CGGG YFFSCCCG-L‡ 6 13 8.8  0.9 NA†
9GGGU YFaFSACCC-L‡ 6 13 16  2 NA†
9UAG THG73-dCA 2 13 4.8  1 100†
9CGGG YFFSCCCG-dCA 2 13 0.42  0.8 8.8†
9GGGU YFaFSACCC-dCA 2 13 0.092  0.02 1.9†
9UAG THG73-dCA 6 13 8.2  1 100†
9CGGG YFFSCCCG-dCA 6 12 1.2  0.3 15†
9GGGU YFaFSACCC-dCA 6 11 0.27  0.09 3.3†
9UAG — — 13 0.37  0.1 100§
9CGGG — — 13 0.085  0.03 23§
9GGGU — — 13 0.078  0.02 21§
NA, not applicable; —, no tRNA.
*Average Imax (in A) recorded at 1 mM ACh.
†THG73.
‡Currents in response to 10 M and 1 mM ACh displayed a ratio of 0.1, as
anticipated from the Hill equation fit for one wild-type receptor.
§UAG.
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YFaFSACCC-L gave dramatic increases in Imax, with a percentage
change of 950%and 630%, respectively (Table 4). This large change
in Imax in response to a modest increase in tRNA concentration
implicates a competition with endogenous triplet tRNA that re-
sponds nonlinearly to the amount of injected FS tRNA. A com-
parable increase in the amount of injected THG73-L led to
complications due to reacylation of the tRNA by endogenous
aaRSs (undesired) and incorporation of natural amino acids other
than leucine, an issue that is addressed in detail in the following
section and in Discussion.
Comparison of Aminoacylation of Suppressor tRNA and Read-Through
of Suppression Sites. To evaluate aminoacylation in vivo, which is
undesirable for any tRNA used to incorporate UAAs, the 9 site
was again studied, because most amino acids produce functional
receptors when substituted at this position (14). In all experiments,
tRNAs that had been ligated to dinucleotide deoxyCA (dCA) but
did not contain an amino acid at the 3 end were injected to more
closely mimic the biologically active, full-length tRNA. To maxi-
mize the potential for aminoacylation by endogenous aaRSs, 2-day
incubations and relatively large mRNA injections (16.5 ng) were
used. Surprisingly, THG73-dCA, which has been used extensively
for UAA incorporation in Xenopus oocytes, showed significant
aminoacylation in vivo, with an Imax of4.8 and8.2 A for 2 and
6 ng of tRNA, respectively (Table 4). Note that under other
conditions (lessmRNAand shorter incubations), previouswork has
found no complications from aminoacylation using THG73-dCA in
Xenopus oocytes (9, 14, 17). Still, the present results establish that
THG73 is susceptible to aminoacylation by aaRSs, which is unde-
sired. No aminoacylation was seen with 2 ng of THG73-L, sug-
gesting that aminoacylation by endogenous aaRSs is more likely
when nonaminoacylated THG73 is injected, as noted previously
(17). Both FS tRNAs showmuch lower amounts of aminoacylation
by aaRSs, as evidenced by the decrease in Imax (Table 4).
YFFSCCCG-dCA shows only 8.8% and 15% of the Imax of THG73-
dCA at 2 and 6 ng, respectively. The most orthogonal suppressor is
YFaFSACCC-dCA, with 1.9% and 3.3% of the Imax of THG73-dCA
at 2 and 6 ng, respectively. The orthogonality trend thus follows the
order: YFaFSACCC-dCA  YFFSCCCG-dCA  THG73-dCA.
YFaFSACCC is the most orthogonal and efficient FS tRNA, and it
therefore offers a viable replacement for THG73, especially when
aminoacylation by aaRSs poses a problem in vivo.
Read-through at the 9 site was also assessed by injection of
mRNA only (Table 4). 9UAG showed the most read-through,
presumably because there is only one in-frame stop codon before
desired termination. 9CGGG and 9GGGU show 23% and
21% read-through, respectively, relative to the UAG stop codon.
This finding is consistent with the idea that an endogenous triplet
tRNA recognizing the first three bases of a quadruplet codon
causes a 1 frameshift, which then presents multiple stop codons.
Again, we designed this experiment to enhance signals from
read-through by injecting large amounts of mRNA (50 ng). No
current was detectable after injection of mRNA containing UAG,
CGGG, or GGGU at position 149, confirming that this site is
much less promiscuous than 9.
Incorporation of Two UAAs. To investigate the simultaneous incor-
poration of two UAAs, we again built on previous work that used
THG73 to incorporate UAAs into the nAChR at positions 149,
9, and 9. Importantly, EC50 changes associated with mutations
at these sites are independent of one another (18, 19), allowing one
to qualitatively anticipate the consequences of multiple mutations.
In particular, both 9Aba and 9Nval produce predictable reduc-
tions in EC50 that should be reproduced when combined with
mutations at149 (14). That is, the previously noted 4-fold increase
in EC50 that is seen when the native tryptophan at 149 is replaced
by WF1 should persist when in combination with 9Aba or
9Nval.
Successful incorporation of two UAAs to produce large ACh-
induced currents could be seen when a 5-fold excess of mutant to
wild-type mRNA was used. Suppression with 149UAG
THG73-W and 9CGGGYFFSCCCG-L is a wild-type recovery
experiment that gave the expected EC50 for ACh of 50 M (Table
5). Maintaining 9CGGGYFFSCCCG-L but substituting
149UAGTHG73-WF1 resulted in the anticipated 4-fold increase
in EC50 (Table 5) (18). For incorporation of two UAAs,
149UAGTHG73-W or WF1 was combined with either
9CGGGYFFSCCCG-Aba or 9GGGUYFaFSACCC-Nval (Ta-
ble 5 and Fig. 2; representative traces are shown in Fig. 4, which is
published as supporting information on the PNAS web site). The
149WF1:WEC50 ratios are 4.4 for the 9 and 9mutants. These
experiments establish that frameshift suppression can be combined
with nonsense suppression to incorporate two UAAs in a eukary-
otic system.
Incorporation of Three UAAs. To demonstrate the incorporation of
three UAAs, we combined the two-UAA incorporation experi-
ments described above, taking advantage of the knowledge that
Table 5. Incorporation of two UAAs
149 tRNA  or  tRNA
EC50
(theoretical)* nH n
UAG THG73-W 9CGGG YFFSCCCG-Aba 14  0.4 (16)† 1.7  0.06 9
UAG THG73-W 9GGGU YFaFSACCC-Nval 41  2 (36)† 1.9  0.1 9
UAG THG73-W 9CGGG YFFSCCCG-L 50  3 (50)‡ 1.4  0.08 20
UAG THG73-WF1 9CGGG YFFSCCCG-Aba 61  3 1.5  0.08 7
UAG THG73-WF1 9GGGU YFaFSACCC-Nval 180  7 1.8  0.1 6
UAG THG73-WF1 9CGGG YFFSCCCG-L 200  7 (200)‡ 1.3  0.04 9
*EC50 values from THG73-UAA incorporation by nonsense suppression.
†Ref. 14.
‡Ref. 18.
Fig. 2. Fits to the Hill equation (for incorporation of two UAAs). Data
correspond to the rows in Table 5 as follows: row 1, open circles; row 2, open
squares; row 4, filled circles; row 5, filled squares. Rows 3 and 6 are left out for
clarity and have previously been reported (Table 3 and ref. 18).








EC50 is lowered monotonically by appropriate 9 mutations at
multiple subunits (20). Thus, one expects a lower EC50 when
9Aba and 9Nval are incorporated simultaneously. Suppression
of 149UAG:9CGGG::9GGGU by using an mRNA ratio of
5:5:1:5 with THG73-W, YFFSCCCG-Aba, and YFaFSACCC-Nval
resulted in functional channel expression with an EC50 of 4.5 M
ACh (Fig. 3), which is lower than either of the two UAAs (Aba or
Nval) incorporated separately. However, the same conditions with
THG73-WF1 yielded only small currents. To obtain more expres-
sion, 149UAG mRNA and THG73-WF1 were initially injected,
and, 24 h later, 9CGGG::9GGGU (5:1:5) was injected with
YFFSCCCG-Aba and YFaFSACCC-Nval (final mRNA ratio of
5:5:1:5). This strategy resulted in adequate expression and an EC50
of 19MACh (Fig. 3). The ratio of the EC50s (149WF1:W) is 4.2,
confirming that three UAAs were simultaneously incorporated
in vivo.
Discussion
The present results establish that frameshift suppression is viable
in a eukaryotic, vertebrate cell and that it can be used to
incorporate multiple UAAs in a single experiment. Previous
work in Xenopus oocytes found that UAA incorporation using
THG73FSACCC was inefficient, and it was proposed that either
the Xenopus translational machinery was not compatible with
frameshift suppression or that THG73FSACCC was a poor tem-
plate for quadruplet recognition (9). Our results support the
second rationalization, and a second FS derived from THG73,
THG73FSCCCG, is also not viable. It thus appears that THG73-
derived FS tRNAs are misfolded, not recognized by the elon-
gation factor EF-Tu, or not accepted by other components of the
translational machinery.
However, frameshift suppression is viable in the Xenopus oocyte
by using either HSFS or YFFS tRNAs. We find that, in Xenopus
oocytes, the quadruplet GGGU is suppressed more efficiently by
both HSFSACCC and YFaFSACCC than the corresponding CGGG
tRNApairs. This difference is seen despite the fact that inXenopus,
the GGG triplet is used twice as frequently (12.9 per 1,000) as the
CGG triplet (21). Frameshift suppression must compete with
endogenous triplet-recognizing tRNAs. Codon usage is apparently
not a perfect predictor of frameshift suppression efficiency.
We have evaluated three different tRNAs: the AS THG73 and
theFSsYFFSCCCG andYFaFSACCC. ForUAA incorporation in the
Xenopus oocyte, both YFFS tRNAs are less efficient than the AS
THG73. This finding parallels results from earlier in vitro studies
(16). Apparently, the competition between release factors and the
AS tRNA is less detrimental than the competition between FS
tRNAs and endogenous, triplet-recognizing tRNA. This view is
supported by the rapid, nonlinear rise in suppression efficiency
when the amount of YFFS tRNA is increased (Table 4). CGGG-
recognizing tRNAs are more sensitive to the amount injected than
GGGU-recognizing tRNAs. Increasing the amount of FS tRNA for
UAA incorporation is essential tomaximize suppression efficiency.
The incorporation of UAAs site-specifically into proteins re-
quires the suppressor tRNA to be orthogonal to the endogenous
aaRSs. Read-through of the suppression site or aminoacylation of
the suppressor tRNA (once the chemically ligated UAA has been
removed) can result in the undesired incorporation of natural
amino acids at the suppression site. The two YFFS tRNAs studied
here exhibit much more orthogonality than THG73 under the
extreme conditions (extended incubation time and increased
mRNA) used in Table 4. However, THG73 is an orthogonal
suppressor tRNA to the Xenopus oocyte when used properly;
THG73 has been used to successfully incorporate100 residues at
scores of sites in 20 different proteins (1, 2). Even promiscuous sites,
such as the 9UAG, can be efficiently suppressed by THG73-
UAA when using less tRNA, mRNA, and incubation time (14).
9UAG injected with THG73-dCA shows no greater current than
mRNA alone with similar conditions. The small current is1% of
typical UAA incorporation experiments and is caused by read-
through of theUAGcodon (17). Voss and coworkers (9) found that
THG73 incorporated three UAAs and Phe with efficiencies of
93.5–99.5% (determined by THG73-UAA incorporation relative
to natural amino acids placed by read-through or aminoacylation of
THG73-dCA) using luciferase expressed in Xenopus oocytes. The
current results show that the YFFS tRNAs are even more orthog-
onal, and so the efficiency of UAA incorporation (relative to
natural amino acids) should be greater than with THG73.
An important contributor to our ability to efficiently incorporate
two and three UAAs is the masking of undesired quadruplets to
prevent loss of UAA. In general, the requirement for masking of
mRNA to remove undesirable quadruplet codons does complicate
the frameshift suppression approach. The only previous examples
of UAA incorporation in higher eukaryotes were performed by
nonsense suppression (1–5, 10). Frameshift suppression may be
limited in vivo to cells that are dormant (such as Xenopus oocytes),
express large quantities of the target mRNA, or come from
genetically engineered organisms. Also, suppressor tRNAs may be
limited to rare codons because of possible toxicity arising from
undesired suppression in other proteins (22).
The combination of nonsense and frameshift suppression allows
one to incorporate multiple UAAs site-specifically into proteins
expressed in Xenopus oocytes. These methods are compatible with
our entire library ofUAAs (2, 23) andwill allow formultipleUAAs
to be incorporated into other ion channels for structure–function
studies, cross-linking, and FRET experiments. In principle, further
quadruplet codons could be used to simultaneously incorporate
more than three UAAs.
Materials and Methods
Materials. All oligonucleotides were synthesized by the California
Institute of Technology Biopolymer Synthesis facility or Integrated
DNA Technologies (Coralville, IA) (sequences are listed in Table
7, which is published as supporting information on the PNAS web
site). NotI was purchased from Roche Applied Science (Indianap-
olis). BamHI, EcoRI, FokI, T4 DNA ligase, and T4 RNA ligase
were purchased from NEB (Beverly, MA). Kinase Max, T7
MEGAshortscript, and T7 mMessage mMachine kits were from
Ambion (Austin, TX). dCA and 6-nitroveratryloxycarbonyl-
protected dCA-UAAwere prepared as reported in refs. 14, 18, and
24. ACh chloride was purchased from Sigma-Aldrich.
Fig. 3. Simultaneous incorporation of three
UAAs. (A) Representative current traces from
oocytes incorporating three UAAs. (B) Dose–
response curves are as follows: 149W, 9Aba,
and 9Nval, open circles; 149WF1, 9Aba,
and 9Nval, filled circles. EC50  4.5  0.4 and
nH 1.7 0.3, and EC50 19 2 and nH 1.3
0.1, respectively. The ratio of the EC50s is 4.2.
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Gene Construction and RNA Preparation. The -, -, -, and -
subunits of nAChRwere previously subcloned in the pAMV vector
(25). All four in-frame CGGGs were mutated (shown in italics) to
degenerate codons (182CGC, 23AGG, 402AGG, and
195AGG), and one GGGT was mutated at the fourth position
(1AGC); these constructs are termed “masked.” 149TAG,
CGGG, GGGT; 9TAG, CGGG, GGGT; and 9GGGT muta-
tions were placed on masked constructs by QuikChange site-
directed mutagenesis (Stratagene). Mutations were verified by
DNA sequencing (at the California Institute of Technology Se-
quencingStructure Analysis Facility). Template DNA was linear-
ized with NotI and mRNA prepared with the T7 mMessage
mMachine kit. mRNA was purified by using the RNeasy Mini kit
(Qiagen, Valencia, CA) and quantified by absorption at 260 nm.
THG73 and HSAS in pUC19 vector were previously made (10,
17). Genes for HSFSCCCG, THG73FSCCCG, and YFFSCCCG (se-
quence from ref. 6) with flanking EcoRI and BamHI overhangs
were phosphorylated by using the Kinase Max kit, annealed, and
ligated with T4 DNA ligase into EcoRI and BamHI linearized
pUC19 vector as described in ref. 24. A73G; C2G, G3C, G4C; and
C69G, C70G, G71C mutations (from ref. 7) were sequentially
placed by QuikChange mutagenesis on the YFFSCCCG construct to
obtain YFaFSCCCG (‘‘a’’ refers to acceptor stem mutations).
HSFSACCC and YFaFSACCC (sequence from ref. 7) were prepared
by replacing the anticodon of HSFSCCCG and YFaFSCCCG with
ACCC by using QuikChange. All mutations were verified by DNA
sequencing (at the California Institute of Technology Sequencing
Structure Analysis Facility). Template DNA for tRNA lacking the
3CA was prepared by FokI digestion, and tRNA was transcribed
by using the T7 MEGAshortscript kit. tRNA was desalted by using
CHROMA SPIN-30 DEPC-H2O columns (BD Biosciences), and
concentration was determined by absorption at 260 nm.
dCA and dCA-UAA Ligation to Suppressor tRNA. dCA and 6-nitro-
veratryloxycarbonyl-protected dCA-UAA were coupled to sup-
pressor tRNA by using T4 RNA ligase for 30 min as described in
refs. 24 and 26, desalted by using CHROMA SPIN-30 DEPC-H2O
columns, and quantified by absorption at 260 nm. tRNA ligation
efficiency was determined byMALDImass spectrometry (26), and
all tRNA dCA or dCA-UAA ligations were 75%.
In Vivo Suppression Experiments. Stage VI oocytes ofXenopus laevis
were prepared as described in ref. 27. All tRNA were refolded at
65°C for 2min, and tRNA-UAAwere deprotected for 5min byUV
irradiation before injection (17). The injection volume for all
experiments was 50 nl, and the incubation time was 44–52 h unless
otherwise noted. Suppression of HSAS and HSFS (1.25 or 2.5 ng
of tRNA) with 20 ng of mRNA in a subunit ratio of 2:5:1:1 for
:9(UAG,CGGG, orGGGU)::was recorded after 1 or 2 days.
Single UAA incorporation was performed by using 20–30 ng of
mRNA in a subunit ratio of 10:1:1:1 for 149(CGGG or
GGGU):::, 2:5:1:1 for :9GGGU::, or 2:1:1:5 for
:::9GGGU with 4.8–16.5 ng of YFFSCCCGYFaFSACCC-
UAA. Comparison of -masked and wild-type suppression con-
tained 25 ng of total mRNA injected in the subunit ratio listed in
Table 6 with 1:1 : and 10 ng of YFaFSACCC-W. For comparison
of suppression efficiency and aminoacylation of tRNA in vivo, all
mRNA was normalized to the same concentration, and 16.5 ng of
mRNA was injected in the subunit ratio 10:1:1:1 for 149(UAG,
CGGG, or GGGU)::: or 2:5:1:1 for :9(UAG, CGGG, or
GGGU):: with tRNA amounts listed in Table 4. For read-
through experiments, 50 ng of mRNA in the ratio 2:5:1:1 for
:9(UAG, CGGG, or GGGU):: was injected. Two UAA
experiments were performed by injection of 20–30 ng of mRNA in
a subunit ratio of 5:5:1:1 for149UAG:9CGGG:: or 5:1:1:5 for
149UAG:::9GGGUwith 10–25 ng of each suppressor tRNA-
UAA. For three UAAs, 149W, 9Aba, and 9Nval, 26 ng of
mRNA in a ratio of 5:5:1:5 for 149UAG:9CGGG::9GGGU
was injected with 20 ng of each suppressor tRNA-UAA, and a
second injection of 33 ng of each tRNA-UAA was done 24 h later.
For 149WF1, 9Aba, and 9Nval, 8 ng of 149UAG mRNA
with 50 ng of THG73-WF1 was injected, and a second injection of
18 ng of mRNA with a subunit ratio of 5:1:5 for
9CGGG::9GGGU with 25 ng of each YFFSCCCG-Aba and
YFaFSACCC-Nval was performed 24 h later; oocytes were recorded
3 days after the first injection.
Electrophysiology. Recordings employed two-electrode voltage
clamp on the OpusXpress 6000A (Axon Instruments, Union City,
CA). ACh was stored at20°C as a 1M stock, diluted in Ca2-free
ND96, and delivered to oocytes by computer-controlled perfusion
system. For HSAS and HSFS experiments, the holding potential
was 60 mV, and all UAA experiments were performed at either
60 or 80 mV. Dose–response data were obtained from at least
nine ACh concentrations, and comparisons were tested at one drug
concentration, except 9(UAG, CGGG, or GGGU) with
tRNA-L, for which two concentrations, 10 M and 1 mM, were
used to check for aminoacylation (Table 4). Dose–response rela-
tions were fit to the Hill equation to determine EC50 and the Hill
coefficient (nH). All reported values are represented as a mean 
SE of the tested oocytes [number (n) is listed with each table].
Supporting Information. Masking experiments, representative
traces for two UAA experiments (149W or WF1 and 9Aba),
and oligonucleotides used in this study are detailed in Fig. 4 and
Tables 6 and 7.
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